Evaluation of clinical staging in chronic lymphocytic leukemia- population-based study

References

• Binet J L, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206
   PubMed Web of Science ®Google Scholar
• Rai K R, Sawitsky A, Cronkite E P, Chanana A D, Levy R N, Pasternack B S. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234
   PubMed Web of Science ®Google Scholar
• Molica S, Mauro F R, Callea V, Gentile M, Giannarelli D, Lopez M, et al. A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2005; 46: 553–560
   PubMed Web of Science ®Google Scholar
• Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. The French Cooperative Group on Chronic Lymphocytic Leukemia. Blood 1990; 75: 1414–1421
   PubMedGoogle Scholar
• Natural history of stage A chronic lymphocytic leukaemia untreated patients. French Cooperative Group on Chronic Lymphocytic Leukaemia. Br J Haematol 1990; 76: 45–47
   Web of Science ®Google Scholar
• Montserrat E, Vinolas N, Reverter J C, Rozman C. Natural history of chronic lymphocytic leukemia: on the progression and progression and prognosis of early clinical stages. Nouv Rev Fr Hematol 1988; 30: 359–361
   PubMedGoogle Scholar
• Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 1987; 60: 2712–2716
   PubMed Web of Science ®Google Scholar
• Montserrat E, Sanchez-Bisono J, Vinilas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukemia: analysis of its prognostic significance. Br J Haematol 1986; 62: 567–575
   PubMed Web of Science ®Google Scholar
• Rozman C, Montserrat E, Rodriguez-Fernandez J M, Ayats R, Vallespi T, Parody R, et al. Bone marrow histologic pattern – the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984; 64: 642–648
   PubMed Web of Science ®Google Scholar
• Damle R N, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S L, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847
   PubMed Web of Science ®Google Scholar
• Hamblin T J, Davis Z, Gardiner A, Oscier D G, Stevenson F K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764–1775
   PubMed Web of Science ®Google Scholar
• Keating M, Lerner S, Kantarjian H, Freireich E, O'Brien S. The serum B2microglobulin level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL). Blood 1995; 86: 606A
   Web of Science ®Google Scholar
• Binet J L, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006; 107: 859–861
   PubMed Web of Science ®Google Scholar
• Call T G, Phyliky R L, Noel P, Habermann T M, Beard C M, O'Fallon W M, et al. Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin Proc 1994; 69: 323–328
   PubMed Web of Science ®Google Scholar
• Molica S, Levato D. What is changing in the natural history of chronic lymphocytic leukemia?. Haematologica 2001; 86: 8–12
   PubMed Web of Science ®Google Scholar
• Rozman C, Bosch F, Montserrat E. Chronic lymphocytic leukemia: a changing natural history?. Leukemia 1997; 11: 775–778
   PubMed Web of Science ®Google Scholar
• Mauro F R, Foa R, Giannarelli D, Cordone I, Crescenzi S, Pescarmona E, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 1999; 94: 448–454
   PubMed Web of Science ®Google Scholar
• Molica S. Progression and survival studies in early chronic lymphocytic leukemia. Blood 1991; 78: 895–899
   PubMed Web of Science ®Google Scholar
• Oscier D G, Stevens J, Hamblin T J, Pickering R M, Fitchett M. Prognostic factors in stage AO B-cell chronic lymphocytic leukaemia. Br J Haematol 1990; 76: 348–351
   PubMed Web of Science ®Google Scholar
• Catovsky D, Fooks J, Richards S. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults. Br J Haematol 1989; 72: 141–149
   PubMed Web of Science ®Google Scholar
• Mandelli F, De Rossi G, Mancini P, Alberti A, Cajozzo A, Grignani F, et al. Prognosis in chronic lymphocytic leukemia: a retrospective multicentric study from the GIMEMA group. J Clin Oncol 1987; 5: 398–406
   PubMed Web of Science ®Google Scholar
• Rozman C, Montserrat E, Feliu E, Granena A, Marin P, Nomdedeu B, et al. Prognosis of chronic lymphocytic leukemia: a multivariate survival analysis of 150 cases. Blood 1982; 59: 1001–1005
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Grever M, Kay N, Keating M J, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997
   PubMed Web of Science ®Google Scholar
• Grabowski P, Hultdin M, Karlsson K, Tobin G, Aleskog A, Thunberg U, et al. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood 2005; 105: 4807–4812
   PubMed Web of Science ®Google Scholar
• Vasconcelos Y, Davi F, Levy V, Oppezzo P, Magnac C, Michel A, et al. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin Oncol 2003; 21: 3928–3932
   PubMed Web of Science ®Google Scholar
• Krol A D, le Cessie S, Snijder S, Kluin-Nelemans J C, Kluin P M, Noordijk E M. Non-Hodgkin's lymphoma in the Netherlands: results from a population-based registry. Leuk Lymphoma 2003; 44: 451–458
   PubMed Web of Science ®Google Scholar
• Maartense E, Hermans J, Kluin-Nelemans J C, Kluin P M, Van Deijk W A, Snijder S, et al. Elderly patients with non-Hodgkin's lymphoma: population-based results in The Netherlands. Ann Oncol 1998; 9: 1219–1227
   PubMed Web of Science ®Google Scholar
• Shanafelt T D, Geyer S M, Kay N E. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004; 103: 1202–1210
   PubMed Web of Science ®Google Scholar
• Molica S, Levato D, Dattilo A. Natural history of early chronic lymphocytic leukemia. A single institution study with emphasis on the impact of disease-progression on overall survival. Haematologica 1999; 84: 1094–1099
   PubMed Web of Science ®Google Scholar
• Oscier D, Fegan C, Hillmen P, Illidge T, Johnson S, Maguire P, et al. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 2004; 125: 294–317
   PubMed Web of Science ®Google Scholar
• Rai K R, Peterson B L, Appelbaum F R, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750–1757
   PubMed Web of Science ®Google Scholar
• A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. The French Cooperative Group on Chronic Lymphocytic Leukemia. Blood 1990; 75: 1422–1425
   PubMedGoogle Scholar
• Catovsky D, Richards S, Hillmen P. Early Results from LRF CLL4: a UK Multicenter Randomized Trial. Blood 2005; 106: 212A
   Web of Science ®Google Scholar
• Pamuk O N, Pamuk G E, Soysal T, Ongoren S, Baslar Z, Ferhanoglu B, et al. Chronic lymphocytic leukemia in Turkey: experience of a single center in Istanbul. South Med J 2004; 97: 240–245
   PubMed Web of Science ®Google Scholar
• Byrd J C, Gribben J G, Peterson B L, Grever M R, Lozanski G, Lucas D M, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006; 24: 437–443
   PubMed Web of Science ®Google Scholar
• Jelinek D F, Tschumper R C, Geyer S M, Bone N D, Dewald G W, Hanson C A, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001; 115: 854–861
   PubMed Web of Science ®Google Scholar
• Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580–1589
   PubMed Web of Science ®Google Scholar